Analytical Data
-
Gene name
ATP13A2
- Application
-
Alternative Names
AT132_HUMAN; Atp13a2; ATPase type 13A2; CLN12; FLJ26510; HSA9947
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NQ11
-
Expression Region
1-1180aa
-
AA Sequence
MSADSSPLVGSTPTGYGTLTIGTSIDPLSSSVSSVRLSGYCGSPWRVIGYHVVVWMMAGIPLLLFRWKPLWGVRLRLRPCNLAHAETLVIEIRDKEDSSWQLFTVQVQTEAIGEGSLEPSPQSQAEDGRSQAAVGAVPEGAWKDTAQLHKSEEAVSVGQKRVLRYYLFQGQRYIWIETQQAFYQVSLLDHGRSCDDVHRSRHGLSLQDQMVRKAIYGPNVISIPVKSYPQLLVDEALNPYYGFQAFSIALWLADHYYWYALCIFLISSISICLSLYKTRKQSQTLRDMVKLSMRVCVCRPGGEEEWVDSSELVPGDCLVLPQEGGLMPCDAALVAGECMVNESSLTGESIPVLKTALPEGLGPYCAETHRRHTLFCGTLILQARAYVGPHVLAVVTRTGFCTAKGGLVSSILHPRPINFKFYKHSMKFVAALSVLALLGTIYSIFILYRNRVPLNEIVIRALDLVTVVVPPALPAAMTVCTLYAQSRLRRQGIFCIHPLRINLGGKLQLVCFDKTGTLTEDGLDVMGVVPLKGQAFLPLVPEPRRLPVGPLLRALATCHALSRLQDTPVGDPMDLKMVESTGWVLEEEPAADSAFGTQVLAVMRPPLWEPQLQAMEEPPVPVSVLHRFPFSSALQRMSVVVAWPGATQPEAYVKGSPELVAGLCNPETVPTDFAQMLQSYTAAGYRVVALASKPLPTVPSLEAAQQLTRDTVEGDLSLLGLLVMRNLLKPQTTPVIQALRRTRIRAVMVTGDNLQTAVTVARGCGMVAPQEHLIIVHATHPERGQPASLEFLPMESPTAVNGVKDPDQAASYTVEPDPRSRHLALSGPTFGIIVKHFPKLLPKVLVQGTVFARMAPEQKTELVCELQKLQYCVGMCGDGANDCGALKAADVGISLSQAEASVVSPFTSSMASIECVPMVIREGRCSLDTSFSVFKYMALYSLTQFISVLILYTINTNLGDLQFLAIDLVITTTVAVLMSRTGPALVLGRVRPPGALLSVPVLSSLLLQMVLVTGVQLGGYFLTLAQPWFVPLNRTVAAPDNLPNYENTVVFSLSSFQYLILAAAVSKGAPFRRPLYTNVPFLVALALLSSVLVGLVLVPGLLQGPLALRNITDTGFKLLLLGLVTLNFVGAFMLESVLDQCLPACLRRLRPKRASKKRFKQLERELAEQPWPPLPAGPLR
-
Molecular Weight
128 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ATP13A2, also known as Parkin-interacting protein or Kufor Rakeb syndrome protein, is a lysosomal ATPase that plays a critical role in cellular homeostasis and neuroprotection. Mutations in the ATP13A2 gene are associated with Kufor Rakeb Syndrome, a rare, autosomal recessive neurodegenerative disorder characterized by juvenile-onset parkinsonism, cognitive decline, and eye movement abnormalities. Research has indicated that ATP13A2 is involved in various cellular processes, including metal ion metabolism, lysosomal function, and autophagy, which are essential for neuronal health. Studies suggest that ATP13A2 may facilitate the transport of cations such as manganese and zinc, thus contributing to cellular ionic balance and preventing neurotoxicity. Recombining ATP13A2 protein offers significant potential for unraveling its biochemical functions and interactions in cellular pathways, paving the way for therapeutic strategies aimed at addressing deficiencies associated with its mutations. Investigating the structure-function relationships and the molecular mechanisms underlying its activity can provide insights into the pathophysiology of related neurodegenerative conditions. Consequently, producing recombinant ATP13A2 protein allows for detailed biochemical analysis, high-throughput screening for inhibitors or activators, and the exploration of its role in lysosomal disorders and synaptic health. Furthermore, understanding the effects of ATP13A2 dysfunction on cellular metabolism and neuronal viability may reveal potential targets for drug development aimed at ameliorating the symptoms of associated disorders. Overall, research on recombinant ATP13A2 not only enhances our knowledge of its physiological roles but also contributes to the broader understanding of lysosomal-related neurodegenerative diseases.
